TON Strategy has completed its legacy business clearance, expected to reduce annual operating costs by $4 million.
Odaily reported that the Nasdaq-listed digital asset reserve company TON Strategy Company (TONX) announced that it has basically completed the winding down of its traditional social e-commerce and software operations inherited from Verb Technology, and has released preliminary results for its June staking business. TON Strategy stated that this adjustment is aimed at optimizing its cost structure and shifting the company’s strategic focus toward managing Gram token reserves and supporting the development of the TON ecosystem. It is reported that this round of winding down mainly involves:
The legacy agency business and livestream shopping services of MARKET.live;
Business related to the LyveCom social e-commerce software.
TON Strategy expects that this adjustment will reduce the company’s annual cash operating expenses by approximately 4 million US dollars, and further simplify its operating structure. The relevant financial impact is expected to begin appearing in the financial report for the second quarter of 2026, and to be fully reflected in subsequent quarters. (Globenewswire)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Starbucks (SBUX.US) officially refutes rumors: clearly denies acquiring Chipotle (CMG.US), focuses on "Back to Starbucks" transformation strategy
Starbucks publicly clarified on Monday that the company has not acquired Chipotle Mexican Grill, putting an end to the previous acquisition rumors.
BlackRock increases allocation to short-term US Treasuries and lowers US stocks: "Rate hike bets have gone too far," high yields should be prioritized
BlackRock has turned bullish on U.S. Treasury bonds for the first time in six years, upgrading short-term bonds to overweight and downgrading U.S. equities to neutral, stating that rate hike expectations are excessive and it is time to lock in yields.

AstraZeneca (AZN.US) Relizumab's new indication is expected to be included in priority review
Relizumab is a blockbuster product under AstraZeneca, with global sales projected to reach 4.718 billions USD in 2025 (YOY +20.23%).
4 Big Bank Earnings to Watch This Week as Wall Street Turns Bullish
